WASHINGTON, D.C. — June 22, 2016 — The Sabin Vaccine Institute is partnering with King Saud University (KSU) in Riyadh, Saudi Arabia, to advance vaccine research and development capacity in the Middle East and North Africa. As part of the new $6.6 million agreement, Saudi scientists will receive technical training in vaccine development at the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) laboratories in Houston, Texas.
Statements and Press Releases
Statement of Dr. Peter Hotez, President of the Sabin Vaccine Institute and Director of its Product Development Partnership on the Group of 7 (G7) Summit, at which the leaders of Japan, the United States, the United Kingdom, Germany, Canada, Italy and France affirmed a commitment to neglected tropical diseases (NTDs).
WASHINGTON, D.C. — April 28, 2016 — The Sabin Vaccine Institute (Sabin) today announced that its Product Development Partnership (Sabin PDP) began a Phase 1 clinical trial of Na-APR-1 (M74)/Alhydrogel® co-administered with Na-GST-1/Alhydrogel in Brazilian adults.
WASHINGTON, D.C., BANGALORE, AMSTERDAM — October 14, 2015 — The Amsterdam Institute for Global Health and Development (AIGHD) and Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today announced a new research and innovation partnership with the Association of Biotechnology Led Enterprises (ABLE) of India on vaccine development for hookworm and other neglected tropical diseases (NTDs). The European Union, through its EuropeAid program, recently awarded a five-year grant of €333,000 to AIGHD to establish this EU-India partnership.